InvestSMART

ImExHS Limited (ASX:IME)

ALERT: Price-sensitive ASX Announcement for IME
Current share price for IME : $0.345 0.125 (56.82%)+
Announcement
Release
2 Sep 2025 9:52AM
Price at Release
$0.220
Full Release
download
Summary
ImExHS Limited's 1H FY25 Results Investor Presentation reported a 4% increase in sales revenue year over year, reaching $13.7 million. The Annual Recurring Revenue (ARR) increased by 11% from the previous year to $32.8 million. The company highlighted its software business, with a significant focus on the IMEXHS Enterprise and Cloud services, which saw a 20% increase in ARR. The Radiology services, primarily in Colombia, reported a 6% increase in ARR. Despite a slight decrease in underlying EBITDA from $1.9 million to $1.3 million for software, the Radiology segment improved its EBITDA from negative to $0.3 million. Strategies discussed included consolidating leadership in the LATAM region, scaling the SaaS model, and achieving cost efficiencies. The launch of Aquila+, an AI-enhanced RIS-PACS suite, was highlighted as a key product development. Forward-looking guidance anticipates revenue growth to $27.5-28.2 million for the full year FY25, with an underlying EBITDA expected to rise between $1.3-1.6 million.
Key Points
  • Sales revenue increased by 4% to $13.7 million.
  • Annual Recurring Revenue (ARR) grew by 11% to $32.8 million.
  • Software ARR increased by 20%, focusing on IMEXHS Enterprise and Cloud.
  • Radiology ARR increased by 6%, with EBITDA improving to $0.3 million.
  • Cost and margin improvement initiatives were implemented.
  • Launch of the AI-enhanced RIS-PACS suite, Aquila+.
  • Guidance for FY25 includes revenue growth and improved EBITDA.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.